You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
科兴延迟公布後期试验结果 许树昌料疫苗未能下月到港
阿思达克 12-24 14:04
《华尔街日报》报道,科兴控股(SVA.US)将推迟至明年1月再公布其新冠疫苗的後期试验结果,由於该公司将把巴西的数据与来自印尼和土耳其的试验结果进行整合。公司原先预期昨日(23日)公布巴西三期临床试验的有效性,惟当地测试机构Butantan Institute表示,科兴要求延长十五日时间分析数据,以及於印尼及土耳其进行的其他疫苗试验的结果。

食物及卫生局局长陈肇始今早表示,预计科兴首批疫苗将於明年1月到港,政府顾问兼中大呼吸系统科讲座教授许树昌表示,科兴延迟公布数据,意味疫苗未能如期於1月到港,最快或要待至2月。现时他预期由复星及BioNTech合作研发的疫苗最快抵港。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.
uSMART
Wealth Growth Made Easy
Open Account